Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Phthalates and Postmenopausal Breast Cancer
Phthalate biomarker concentrations did not result in an increased risk of developing invasive breast cancer, according to results from a prospective subgroup analysis of women enrolled in the Women’s Health Initiative (WHI).1 Although the study authors didn’t observe a large increase in invasive breast cancer risk as concentrations of phthalate biomarkers increased, they also “weren’t able… -
Tumor Hypoxia and Breast Cancer Risk
A well-known means to differentiate between normal and malignant tumors is tissue hypoxia, and a recent study confirmed “extensive intertumor- and intratumor-type heterogeneity in tumor hypoxia” in 8006 tumors across 19 tumor types.The study authors noted “subsets of patients with a range of solid tumors with genetic instability may benefit from hypoxia-targeting therapy.”For community oncologists, study… -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
Drug Resistance to CDK4/6 Inhibitors
Comparing Ribociclib and Palbociclib
Ribociclib, Abemaciclib, and Palbociclib
The Potential of CDK4/6 Inhibitors
How Cyclin D Plays A Role
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
First Cancer Immunotherapy Regimen Approved for Breast Cancer Treatment
Fixed-Dose Trastuzumab in Early-Stage HER2-Positive Breast Cancer: Unanswered Questions
Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer
American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer
